Compare HXL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HXL | GPCR |
|---|---|---|
| Founded | 1946 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 6.3B |
| IPO Year | 1994 | 2023 |
| Metric | HXL | GPCR |
|---|---|---|
| Price | $81.02 | $51.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $81.73 | ★ $103.36 |
| AVG Volume (30 Days) | ★ 1.2M | 840.0K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,893,900,000.00 | N/A |
| Revenue This Year | $10.20 | N/A |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $45.28 | $13.24 |
| 52 Week High | $95.22 | $94.90 |
| Indicator | HXL | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 28.63 |
| Support Level | $80.25 | $18.36 |
| Resistance Level | $84.64 | $93.91 |
| Average True Range (ATR) | 2.60 | 3.56 |
| MACD | -1.40 | -0.38 |
| Stochastic Oscillator | 23.33 | 6.11 |
Founded in 1948, Hexcel designs and manufactures a range of highly engineered composite fibers, fabrics, resins, and structures for use in the commercial aerospace, defense, and high-performance automotive markets. These are lighter than metal and perform under rigorous conditions in aircraft frames, wings, engines, and other components and subassemblies. The company's name derives from the six-sided honeycomb structures that lend many of its products their light weight and rigidity. Hexcel's biggest customers are Airbus (40% of 2024 sales) and Boeing (15% of 2024 sales; 25% before the pandemic) and their respective subcontractors.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.